The pleiotropic functions of peroxisome proliferator-activated receptor γ

Journal of Molecular Medicine

Volumn 79, Issue 1, 2001, Pages 30-47

  Debril, Marie Bernard ^a   Renaud, Jean Paul ^a   Fajas, Lluis ^a   Auwerx, Johan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adipogenesis; Insulin resistance; Nuclear receptor; Obesity; Thiazolidinediones; Type 2 diabetes

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; FATTY ACID DERIVATIVE; GW 0072; HORMONE RECEPTOR; INSULIN; L 764406; LIGAND; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REGLITAZAR; RETINOID X RECEPTOR; ROSIGLITAZONE; TROGLITAZONE; TYROSINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CANCER; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INSULIN SENSITIVITY; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PEROXISOME; PROTEIN EXPRESSION; REVIEW;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; COLON; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN; MICE; NEOPLASMS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035094340     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000145     Document Type: Review

References (202)

1. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
2. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression
3. The nuclear receptor superfamily: The second decade
4. Organization, promoter analysis and expression of the human PPARγ gene
5. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
6. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene
7. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms
8. PPARγ3 mRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter
9. PPARγ, the ultimate thrifty gene
10. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: No alterations in adipose tissue of obese and NIDDM patients
11. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
12. Gene expression profile of aging and its retardation by caloric restriction
13. Depot-specific differences in adipose tissue gene expression in lean and obese subjects
14. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes
15. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
16. TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression
17. Decreased expression of murine PPARγ in adipose tissue during endotoxinemia
18. Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus
19. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects
20. Troglitazone effects on muscle gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor γ
21. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation
22. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
23. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
24. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
25. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
26. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
27. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ
28. Effect of a new oral antidiabetic agent CS-045 in NIDDM subjects
29. Effect of troglitazone in insulin-treated patients with type II diabetes
30. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
31. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
32. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes
33. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
34. Rosiglitazone
35. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
36. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety
37. Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ
38. Insulin and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
39. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase
40. c-Jun N-terminal kinase phosphorylates peroxisome proliferator- activated receptor-gamma1 and negatively regulates its transcriptional activity
41. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
42. Interdomain communication regulating ligand binding by PPAR gamma
43. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1
44. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: Integration of hormone signaling in reproduction and stress
45. Adipogenesis and obesity: Rounding out the big picture
46. Transcriptional control of adipogenesis
47. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro
48. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
49. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα
50. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins
51. Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis
52. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids
53. CAAT/Enhancer binding proteins directly modulate transcription from the peroxisome proliferator activated receptor γ2 promoter
54. Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ1) and PPARγ2 mRNA expession in early stages of adipogenesis
55. ADD1: A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation
56. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism
57. Regulation of PPARγ expression by ADD-1/SREBP-1: Implications for adipocyte differentiation and metabolism
58. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity
59. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors
60. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ
61. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
62. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene
63. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
64. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation
65. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators
66. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene
67. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
68. Peroxisome proliferator-activated receptors, orphans with ligands and functions
69. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in PPARγ-expressing tissue
70. Leptin
71. Thiazolidinediones repress ob gene expression via activation of PPARγ
72. Down-regulation of the expression of the obese gene by antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice
73. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
74. The adipocyte specific transcription factor, C/EBPα modulates human ob gene expression
75. The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha
76. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter
77. PPARg mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
78. A macrophage factor inhibits adipocyte gene expression; an in vitro model for cachexia
79. Cachectin (tumor necrosis factor): A macrophage hormone governing cellular metabolism and inflammatory response
80. CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor
81. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP)
82. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signalling
83. Adipose tissue expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance
84. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
85. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity induced insulin resistance
86. Tumor necrosis factor α inhibits signaling from the insulin receptor
87. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
88. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance
89. BRL 49653 blocks lipolytic actions of tumor necrosis factor-alpha: A potential new insulin-sensitizing mechanism for thiazolidinediones
90. Genetics of body-weight regulation
91. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
92. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index
93. Human peroxisome proliferator-activated receptor gamma 2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsable for lipoatrophic diabetes
94. Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations
95. Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: Identification of a Pro12Ala PPARgamma 2 missense mutation
96. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes
97. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
98. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ)
99. Troglitazone action is independent of adipose tissue
100. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
101. Daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans
102. Autonomous control of cell and organ size by CHICO, a drosophila homolog of vertebrate IRS1-4
103. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
104. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes
105. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
106. Insulin resistance-mechanisms, syndromes, and implications
107. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: A model for congenital generalized lipodystrophy
108. Life without fat: A transgenic mouse
109. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation
110. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years
111. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs
112. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin
113. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
114. Modulation of insulin activities by leptin
115. Leptin inhibits glycogen synthesis in isolated soleus muscle of obese (ob/ob) mice
116. Leptin impairs metabolic actions of insulin in isolated rat adipocytes
117. Acute stimulation of glucose metabolism in mice by leptin treatment
118. Adipsin and complement factor D activity: An immune-related defect in obesity
119. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue
120. A novel serum protein similar to C1q, produced exclusively in adipocytes
121. AdipoQ is a novel adipose-specific gene dysregulated in obesity
122. The glucose-fatty acid cycle: Its role in insulin sensitivity and metabolic disturbances of diabetes mellitus
123. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
124. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat
125. Correction of elevated glucose and triglycerides in Zucker diabetic fatty rats by thiazolidinediones parallels increased I-glycogen synthase and lipoprotein lipase activity in muscle and fat
126. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes
127. Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene
128. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ
129. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
130. A canonical structure for the ligand-binding domain of nuclear receptors
131. The nuclear receptor ligand-binding domain: Structure and function
132. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid
133. Molecular basis of agonism and antagonism in the oestrogen receptor
134. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand
135. Ligand-induced stabilization of PPARgamma MONITORED by NMR spectroscopy: Implications for nuclear receptor activation
136. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
137. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors
138. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
139. A signature motif in transcriptional coactivators mediates binding to nuclear receptors
140. Structure and specificity of nuclear receptor-coactivator interactions
141. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
142. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
143. Asymmetry in the PPAR gamma-RXR alpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
144. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains
145. The RXR heterodimers and orphan receptors
146. Lipid mediator networks in cell signaling: Update and impact of cytokines
147. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
148. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
149. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
150. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
151. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
152. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
153. PPARγ agonists inhibit production of monocyte inflammatory cytokines
154. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation
155. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase
156. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase
157. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo
158. A novel therapy for colitis utilizing PPARgamma ligands to inhibit the epithelial inflammatory response
159. 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
160. Peroxisome proliferator activated receptor γ, CCAAT/enhancer binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation
161. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
162. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis
163. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
164. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
165. Terminal differentiation of human breast cancer through PPARγ
166. Ligand for peroxisome proliferator activated receptor γ (troglitazone) has potent anti-tumor effects against human prostate cancer both in vitro and in vivo
167. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells
168. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells
169. Differentiation and reversal of malignant changes in colon cancer through PPARγ
170. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer
171. Activation of peroxisome proliferator-activated receptors alpha and gamma induces apoptosis of huma monocyte-derived macrophages
172. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
173. Loss-of-function mutations in PPARgamma associated with human colon cancer
174. Min/+ mice
175. Activators of the nuclear receptor PPARγ enhance colon polyp formation
176. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
177. Identification and characterization of the familial adenomatous polyposis coli gene
178. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
179. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients
180. Molecular diagnosis of familial adenomatous polyposis
181. Serum immunoreactive-leptin concentrations in normal-weight and obese humans
182. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
183. Lessons from heriditary colorectal cancer
184. Aspirin use and reduced risk of fatal colon cancer
185. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
186. Chemoprevention of spontaneous intestinal adenoma in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam
187. Dietary factors and risk of colon cancer
188. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice
189. PPAR-delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
190. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
191. Diverse signaling pathways modulate nuclear receptor recruitment of N- CoR and SMRT complexes
192. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
193. Retinoid X receptor signaling in the developing spinal cord
194. Feedback-inducible nuclear-receptor-driven reporter gene expression in transgenic mice
195. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor α and γ. Effect of PPARα activation on normal lipid metabolism in liver of Zucker fatty rats
196. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidininedione derivative
197. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates
198. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding
199. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties
200. The structure activity relationship between peroxisome proliferator activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones
201. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice
202. SETOR: Hardware-lighted three-dimensional solid model representations of macromolecules